SGLT2: Why Diabetes Drugs Make You Pee Sugar

Every day your kidneys filter about 180 grams of glucose out of your blood — and normally claw every last gram back before it reaches the urine. The tiny machine doing most of that work is SGLT2, a transporter that rides the sodium gradient to drag sugar back into the blood for free. Watch glucose flow down the tubule and get grabbed at each transporter — then push blood sugar past the renal threshold (~180 mg/dL) and watch the machines saturate and sugar spill into the urine. Finally, hit the SGLT2 inhibitor and watch a modern diabetes drug switch the transporter off on purpose — dumping sugar into the toilet to bring blood sugar down.

Try this: start on Normal and see the urine beaker stay empty, then switch to Diabetes and watch sugar overflow past the transporters — then hit SGLT2 inhibitor and watch the same overflow happen on purpose while the blood-sugar readout falls.

The Science in Plain Language

A bag of sugar, filtered and reclaimed — every single day

Your two kidneys push about 180 litres of blood-derived fluid through their filters each day (that's the glomerular filtration rate, GFR — roughly 125 mL every minute). Because that filtrate starts out with the same sugar concentration as your blood, a person with normal blood glucose filters roughly 180 grams of glucose per day into the tubules — a good-sized bag of sugar. If you did nothing about it, you would lose all of that sugar (and its calories) down the toilet. Instead, the very first stretch of the tubule — the proximal tubule — reclaims essentially 100% of it before the fluid ever becomes urine. Healthy urine has no detectable glucose at all.

SGLT2: the workhorse that rides sodium uphill for free

The star of the show is SGLT2 (sodium-glucose cotransporter 2), studded along the brush-border membrane of the early proximal tubule. It reabsorbs about 90% of the filtered glucose; a higher-affinity cousin, SGLT1, mops up the remaining ~10% further downstream. Here's the clever part. Pumping glucose back into the cell means moving it against its concentration gradient — that costs energy. SGLT2 doesn't burn ATP directly. Instead it grabs one sodium ion (Na⁺) and one glucose together and lets sodium's own strong inward pull drag the glucose along for the ride. This is called secondary active transport: the sugar rides sodium's gradient like a passenger on a train it didn't pay for. SGLT2 uses a 1 sodium : 1 glucose ratio; SGLT1, working where glucose is scarcer, uses a stronger 2 sodium : 1 glucose pull.

GLUT2 and the Na⁺/K⁺ pump: the exit door and the battery

Once inside the tubule cell, glucose leaves the other side through GLUT2, a passive door on the blood-facing (basolateral) membrane, and drifts back into the peritubular capillary — into your circulation. But the whole system only works because sodium keeps flowing inward, and that only stays true if the cell keeps its internal sodium low. That job belongs to the Na⁺/K⁺-ATPase, the pump you can see flashing on the left. Burning one ATP, it ejects 3 Na⁺ out into the blood and pulls 2 K⁺ in, keeping intracellular sodium low so there is always a gradient for SGLT2 to exploit. It is the battery; SGLT2 is the machine that plugs into it. This is the same pump you can explore on the kidney nephron page.

The renal threshold: why sugar spills at about 180 mg/dL

There is a ceiling. Each transporter can only cycle so fast, so together they have a maximum reabsorption rate — the transport maximum (Tm), about 375 mg/min in men and ~300 mg/min in women. As blood sugar climbs, more glucose is filtered; below a certain point every gram is still reclaimed. But once blood glucose passes the renal threshold — classically about 180 mg/dL (10 mmol/L) — the transporters saturate. Any glucose beyond what they can grab flows straight past into the urine. That overflow is glucosuria, and it is the classic laboratory footprint of diabetes: sugar in the urine means blood sugar has been running high enough, long enough, to overwhelm the kidney's remarkable reabsorption machinery. (The threshold varies a little between people, roughly 160–200 mg/dL, and can shift in pregnancy.)

The old test: doctors who tasted urine to find diabetes

Long before glucose meters, physicians diagnosed diabetes by tasting the urine — sweet urine meant sugar was spilling. The full old name, diabetes mellitus, literally means “siphon, honey-sweet.” That sweetness was the renal threshold being exceeded, exactly what you can trigger above by switching to Diabetes or hitting the Sugar load button. It's a striking thought: a 3,000-year-old diagnostic sign is simply SGLT2 running out of capacity. Myth to retire: sugar in the urine does not mean you ate too much sugar that day. It reflects how high your blood glucose climbed relative to your threshold — or, as we'll see, a drug (or a harmless gene) that lowers the threshold on purpose.

The “-flozins”: draining sugar into the urine on purpose

Here's the twist that turned a filtering quirk into a blockbuster class of drugs. SGLT2 inhibitors — the “-flozins”: empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), and ertugliflozin — deliberately block SGLT2. With the workhorse switched off, roughly 50–80 grams of glucose (about 200–320 kcal) are dumped into the urine every day. Blood sugar falls — and crucially, it falls independent of insulin. The drug doesn't ask the pancreas to make more insulin or the tissues to respond better; it simply opens a drain in the kidney. That's why it works even in people whose insulin system is exhausted, why it rarely causes low blood sugar on its own, and why it brings a modest bonus of weight and blood-pressure reduction (you also lose some water — a mild osmotic diuresis). Second myth to retire: these drugs do not work by boosting insulin.

The surprise no one predicted: hearts and kidneys

SGLT2 inhibitors were designed as sugar-lowering drugs, but their biggest headline turned out to have little to do with sugar. Large randomized trials — EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), and DECLARE-TIMI 58 (dapagliflozin) — found meaningful reductions in cardiovascular death and, especially, in hospitalization for heart failure. Follow-up trials extended the benefit to people without diabetes: DAPA-HF and the EMPEROR program showed heart-failure benefit, while CREDENCE and DAPA-CKD showed the drugs slow the progression of chronic kidney disease. The exact reasons are still being worked out — less strain on the heart, gentler pressure inside the kidney's filters, a shift toward burning ketones for fuel — but the practical upshot is real: for many patients these are now heart- and kidney-protective drugs that happen to also lower sugar.

Trade-offs, and what to actually watch for

Peeing out sugar has predictable downsides. The most common is genital yeast infections (and urinary infections): sugar-rich urine is food for Candida, so mycotic infections rise, more so in women. Because you also lose water, there can be volume depletion — lightheadedness, low blood pressure, or dehydration, particularly in older adults or with diuretics. A rare but serious risk is euglycemic diabetic ketoacidosis (DKA): ketones can climb to dangerous levels while blood sugar still looks near-normal, which can hide the emergency — a reason these drugs are usually paused around surgery, serious illness, or very low-carb fasting. Rarer still is a severe genital infection called Fournier's gangrene. And an early, expected small dip in eGFR that looks alarming on labs is actually part of how the drug protects the kidney long-term. None of this is a reason to fear the class — it's a reason to use it thoughtfully.

What the numbers on the screen mean

To keep the animation honest: the real figures are ~180 g of glucose filtered per day, the ~180 mg/dL renal threshold, GFR ~180 L/day, SGLT2 doing ~90% of reabsorption with SGLT1 the rest, and the sodium-to-glucose ratios. The illustrative parts are the individual particles, the precise grams shown in the urine beaker, and how fast blood sugar falls under the inhibitor — a real patient's response depends on kidney function, diet, and dose. One lovely real-world footnote that proves the whole idea is safe: some people are born with harmless mutations in SLC5A2, the gene for SGLT2 — a condition called familial renal glucosuria. They spill glucose in their urine their whole lives with no ill effects. Nature ran the experiment first; the -flozins simply do it on demand.

↑ Back to the animation

Connections

• All Interactive Visualizations
• Kidney Nephron
• Blood Sugar & Insulin
• Inside the Beta Cell
• Type 2 Diabetes